Description

Lazolvan Syrup 15 mg/5 ml. 200 ml

Ingredients

Active ingredient: Each 5 ml of Lazolvan syrup contains 15 mg of Ambroxol hydrochloride. Other inactive ingredients include sucrose, glycerol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, citric acid monohydrate, sodium benzoate, and purified water.

Dosage

Recommended dosage: Adults and children over 12 years: 10 ml (30 mg) 3 times a day. Children 6-12 years: 5 ml (15 mg) 2-3 times a day. Children 2-6 years: 2.5 ml (7.5 mg) 3 times a day. The syrup should be taken with a sufficient amount of liquid.

Indications

Lazolvan syrup is indicated for the treatment of acute and chronic respiratory diseases associated with abnormal mucus secretion and impaired mucus transport.

Contraindications

Do not use Lazolvan syrup in case of known hypersensitivity to Ambroxol or any other ingredients in the product. It is not recommended for use in the first trimester of pregnancy.

Directions

Shake well before use. Use the provided measuring cup for accurate dosage. The syrup can be taken with or without food. Ensure an adequate intake of fluids during treatment.

Scientific Evidence

Ambroxol, the active ingredient in Lazolvan syrup, has been extensively studied for its mucolytic and expectorant properties. Research has shown that Ambroxol enhances the production of pulmonary surfactant, reduces the viscosity of mucus, and improves mucociliary clearance, making it an effective treatment for respiratory conditions.

Additional Information

Storage: Store Lazolvan syrup below 25°C in a dry place. Keep it out of reach of children. Side effects: Common side effects may include gastrointestinal disturbances, allergic reactions, or skin rashes. If any adverse effects occur, discontinue use and consult a healthcare professional.

Pharmacologically, Ambroxol acts by stimulating the production of surfactant in the lungs, which helps in the clearance of mucus and improves breathing. It also exhibits antioxidant and anti-inflammatory properties, further aiding in the management of respiratory conditions.

Clinical trials have demonstrated the efficacy of Lazolvan syrup in conditions such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). In a study by Zheng et al., Ambroxol was found to significantly improve lung function and reduce exacerbations in patients with COPD, highlighting its therapeutic benefits.